A Hospital Antibiotic's Closely Watched Launch
Executive Summary
Cubist ultimately wants its new hospital antibiotic Cubicin to replace the widely used vancomycin. To do that, it's got to demonstrate that Cubicin, recently approved for a single indication, is safe and effective for a broad spectrum of hard-to-treat infections. As the first company in four years to launch a new hospital antibiotic, Cubist may be a model for the handful of other small companies seeking to capitalize on the opportunity. These start-ups may be better suited than Big Pharma to address what experts see as an important but limited unmet medical need.
You may also be interested in...
Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.
Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.
Biovertis AG
Intercell AG spin-out Biovertis AG aims to leverage its parent company's vaccine antigen discovery platform to pinpoint novel targets for anti-infective drugs. Vienna-based Biovertis employs a structure-based drug discovery program; a recent Series A should fund the company into 2007.